Business Context and Reporting Period
This Form 8-K was filed by Novus Therapeutics, Inc. on November 6, 2017. The report discloses a significant change in executive leadership effective as of the filing date.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
- Executive Appointment: Catherine C. Turkel was appointed President, effective November 6, 2017.
- Role Transition: Gregory J. Flesher ceased serving as President but continues as Chief Executive Officer and Board member.
- Compensation Package: Dr. Turkel received an annual salary of $350,000 and a target bonus of 40% of her base salary.
- Equity Grant: Dr. Turkel was granted an option to purchase 50,000 shares of common stock under the 2014 Stock Incentive Plan.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It notes that there were no undisclosed arrangements regarding Dr. Turkel's selection and no family relationships or material interests requiring disclosure under Regulation S-K.
Investor Verification Checklist
- Verify the vesting schedule of the 50,000 share option granted to Dr. Turkel (12,500 shares on the first anniversary, remainder ratably over three years).
- Confirm the exercise price of the stock option, which is tied to the closing price on the grant date.
- Review the Company's 2014 Stock Incentive Plan terms to understand dilution implications.
- Monitor future filings for any changes in the Company's strategic direction following the leadership transition.